AP NEWS

Investigation Report on the Chinese Thymopentin Market 2018: Analysis through 2013 to 2022 - ResearchAndMarkets.com

July 10, 2018

DUBLIN--(BUSINESS WIRE)--Jul 10, 2018--The “Investigation Report on Chinese Thymopentin Market, 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

In 1985, Thymopentin for Injection was launched in Italy in the trade name of “Timunox”. In 1997, Hainan Zhonghe Pharmaceutical Co., Ltd. first launched Thymopentin for Injection (trade name: Hexin), China’s first two-way immunomodulator of synthetic polypeptide after independent research and development. The product once played an important role in the fight against SARS in 2003.

Later, other enterprises including Beijing SL Pharmaceutical Co., Ltd. were approved to produce Thymopentin. Because of a low technological barrier, there are many manufacturers and fierce competitions in the market. Thymopentin is only sold in China as a Chinese-style drug.

According to research, in 2017, the sales value of Thymopentin exceeded CNY 1 billion in the Chinese market dominated by Hainan Zhonghe Pharmaceutical Co., Ltd., Beijing SL Pharmaceutical Co., Ltd., Beijing Sciecure Pharmaceutical Co., Ltd. and Hybio Pharmaceutical Co., Ltd.

The sales value of top 10 enterprises took up about 99% of the market. The sales value of Hainan Zhonghe ranked first with a market share over 30%. It is expected that the Chinese Thymopentin still has large potential to grow in the coming years.

Companies Featured

Beijing SL Pharmaceutical Co., Ltd. Beijing Sciecure Pharmaceutical Co., Ltd. Chengdu DIAO Jiuhong Pharmaceutical Factory Hainan Zhonghe Pharmaceutical Co., Ltd. Henan Furen Huaiqingtang Pharmaceutical Co., Ltd. Hybio Pharmaceutical Co., Ltd. Shanghai Huayuan Pharmacy (Ningxia) Shasai Pharmaceutical Co., Ltd. Sinopharm A-Think Pharmaceutical Co., Ltd. Wuhan Hualong Bio-pharmaceutical Co., Ltd. Yangtze River Pharmaceutical (Group) Co., Ltd.

Key Topics Covered

1 Relevant Concepts of Thymopentin

2 Market Overview of Thymopentin in China

3 Sales of Thymopentin in China, 2013-2017

4 Investigation on Market Share of Major Thymopentin Manufacturers in China, 2013-2017

5 Thymopentin in Different Dosage Forms, 2013-2017

6 Reference Sale Price of Major Thymopentin Products in Chinese Market, 2017-2018

7 Major Thymopentin Manufacturers in China, 2013-2017

8 Prospects of Chinese Thymopentin Market, 2018-2022

For more information about this report visit https://www.researchandmarkets.com/research/4vr5qt/investigation?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180710005902/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs

KEYWORD: ASIA PACIFIC CHINA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/10/2018 01:55 PM/DISC: 07/10/2018 01:55 PM

http://www.businesswire.com/news/home/20180710005902/en

AP RADIO
Update hourly